《辉瑞公司Pfizer Inc.（PFE）2024年第三季度收益电话会议演示报告「NYSE」（英文版）（31页）.pdf》由会员分享，可在线阅读，更多相关《辉瑞公司Pfizer Inc.（PFE）2024年第三季度收益电话会议演示报告「NYSE」（英文版）（31页）.pdf（31页珍藏版）》请在三个皮匠报告上搜索。

1、1Third Quarter 2024Earnings TeleconferenceOctober29,2024Third Quarter 2024 Earnings2IntroductionFrancesca DeMartinoChief Investor Relations Officer,Senior Vice PresidentThird Quarter 2024 Earnings3Our discussions during this conference call will include forward-looking statements that are subject to

2、 substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.We include forward-looking statements about,among other topics,our anticipated operating and financial performance,including financial guidance and projections

3、;changes to Pfizers commercial organization;reorganizations;business plans,strategy,goals and prospects;our Environmental,Social and Governance(ESG)priorities,strategy and goals;expectations for our product pipeline,in-line products and product candidates,including anticipated regulatory submissions

4、,data read-outs,study starts,approvals,launches,clinical trial results and other developing data,revenue contribution and projections,potential pricing and reimbursement,potential market dynamics,including demand,market size and utilization rates and growth,performance,timing of exclusivity and pote

5、ntial benefits;strategic reviews;capital allocation objectives;an enterprise-wide cost realignment program(including anticipated costs,savings and potential benefits);a manufacturing optimization program to reduce our cost of goods sold(including anticipated costs,savings and potential benefits);div

6、idends and share repurchases;plans for and prospects of our acquisitions,dispositions and other business development activities,including our December 2023 acquisition of Seagen,and our ability to successfully capitalize on growth opportunities and prospects;manufacturing and product supply;our ongo